Medical Oncology

Dr. Henry Chi Hang Fung to Oversee Bone Marrow Transplant Services at Fox Chase Cancer Center

A well-known leader in the field of blood diseases and bone marrow transplantation, Dr. Fung has joined Fox Chase Cancer Center. and will also be Director of the Temple University Hospital Bone Marrow Transplant Program.
Read more »

Fox Chase’s Paul F. Engstrom, MD, to Receive Association of Community Cancer Centers Annual Clinical Care Achievement Award

Engstrom has devoted his professional and academic career to improving cancer prevention and early detection research and service.
Read more »

Richard I. Fisher, MD, Named President and CEO of Fox Chase Cancer Center

Since his arrival Fisher has demonstrated adroit and sure-handed leadership and administrative ability, working closely with leaders at Fox Chase and across Temple Health.
Read more »

The Medical Oncology department provides quality diagnosis, treatment, and care for patients with cancer.

Medical Oncology Staff List

Paul F. Engstrom, MD, Acting Director, Medical Oncology

David Eli Adelberg, MD, Attending Physician, Medical Oncology, AtlantiCare Cancer Institute

Igor Astsaturov MD, PhD, Attending Physician, Gastrointestinal Oncology

Stefan Barta MD, MS, MRCP (UK), Attending Physician , Hematologic Oncology

Marijo Bilusic, MD, PhD, Attending Physician, Genitourinary Oncology

Hossein Borghaei, DO, Chief, Thoracic Medical Oncology
Director, Lung Cancer Risk Assessment

Yanis Boumber, MD, PhD, Attending Physician, Neuro-oncology, Thoracic Oncology

Robert Carlson, MD, Attending Physician, Medical Oncology

Jonathan D. Cheng, MD, Attending Physician, Gastrointestinal Oncology

Steven J. Cohen MD, Chief, Gastrointestinal Medical Oncology

Crystal S. Denlinger, MD, Attending Physician, Gastrointestinal Oncology

Efrat Dotan, MD, Attending Physician, Breast Cancer, Gastrointestinal Oncology

Scot W. Ebbinghaus, MD, Attending Physician, Genitourinary Oncology, Thoracic Oncology

Richard I. Fisher, MD, President and CEO, Fox Chase Cancer Center
Attending Physician,
Hematologic Oncology

Henry Chi Hang Fung, MD, FRCPE, Director, Bone Marrow Transplant Program,
Director, Hematologic Oncology Treatment

Daniel M. Geynisman, MD, Attending Physician, Genitourinary Oncology

Lori Goldstein, MD, Director, The Naomi and Phil Lippincott Breast Evaluation Center

Gary R. Hudes, MD, Director, Genitourinary Malignancies

Angela Jain, MD, Attending Physician, Gynecologic Oncology

Nadia Khan, MD, Attending Physician, Hematologic Oncology

Patricia L. Kropf, MD, Assistant Director, Bone Marrow Transplant Program

Gregory Michael Lubiniecki, MD, Attending Physician, Genitourinary Oncology, Thoracic Oncology

Lainie P. Martin, MD, Attending Physician, Gynecologic Oncology

Mary Ellen Martin, MD, FACP, Assistant Director, Bone Marrow Transplant Program

Ranee Mehra, MD, Attending Physician, Thoracic Oncology

Michael M. Millenson, MD, Director, Hematology Service

Sujana Movva, MD, Attending Physician, Sarcoma

Anthony J. Olszanski, MD, RPh, Co-Director, Cutaneous Oncology Program,
Director, Phase I Program, Clinical Trials,
Director, Clinical Pharmacology

Elizabeth Plimack, MD, MS, Attending Physician, Genitourinary Oncology

Vijay Sandilya, MD, Attending Physician, Medical Oncology,
Attending Physician, AtlantiCare

Jennifer Yuchen Shih, MD, MS, Attending Physician, Breast Cancer Treatment

Joseph Treat, MD, Attending Physician, Thoracic Oncology

Margaret von Mehren, MD , Director, Sarcoma Program

Yu-Ning Wong, MD, MSCE, Attending Physician, Genitourinary Oncology

 

Pain and Palliative Care

Michael H. Levy, MD, PhD, Vice Chair, Medical Oncology, 
Director, Pain and Palliative Care

Marcin Chwistek, MD, Attending Physician, Medical Oncology

Advanced Practice Clinicians

 

 

Traditional chemotherapy and new clinical trials provide our Medical Oncologists with access to a tremendous range of new anticancer treatments, including medicines and combinations of medicines.

"Personalized" treatment involves identifying characteristics of individual patients' tumors in order to determine their responsiveness to specific chemotherapy drugs. The ultimate goal of such analysis is to determine which tumors are sensitive to a given drug and equally important, which tumors are resistant to specific drugs.

A similar approach has already benefited the Fox Chase Gastrointestinal Cancer program, where patients with metastatic colorectal cancer are routinely screened for mutations in the K-RAS gene to determine the most effective drug treatment. Fox Chase's Clinical Molecular Genetics Laboratory has been conducting this test since 2007.

This focus on personalized medicine is just another example of Fox Chase's leadership in bringing state-of-the-art research directly to the bedside and delivering expert and compassionate care with the goal of improving patient outcomes.